Perkins Coie Trust Co Lowers Stake in Medtronic PLC $MDT

Perkins Coie Trust Co decreased its position in Medtronic PLC (NYSE:MDT) by 96.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,985 shares of the medical technology company’s stock after selling 1,115,440 shares during the quarter. Perkins Coie Trust Co’s holdings in Medtronic were worth $3,808,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in MDT. Vanguard Group Inc. raised its holdings in shares of Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after buying an additional 1,895,165 shares during the period. Geode Capital Management LLC boosted its holdings in Medtronic by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock valued at $2,448,699,000 after acquiring an additional 310,684 shares during the period. Bank of New York Mellon Corp grew its position in Medtronic by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 21,275,850 shares of the medical technology company’s stock valued at $1,854,616,000 after acquiring an additional 595,549 shares in the last quarter. Invesco Ltd. increased its stake in Medtronic by 3.9% during the second quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after purchasing an additional 666,557 shares during the period. Finally, Norges Bank acquired a new stake in shares of Medtronic during the second quarter worth about $1,432,698,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic filed an S-1 to take its Diabetes unit, MiniMed, public — the preferred separation path is an IPO followed by a split-off. Management says the move is part of a planned separation aimed at creating two focused companies, which could unlock value and provide strategic clarity. Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed
• Positive Sentiment: Regulatory and product progress: Medtronic (and peers) secured FDA nods for liquid embolic systems — a reminder the company continues to advance therapeutic devices that can support organic growth beyond the diabetes separation. Medtronic, J&J MedTech both get FDA nods for liquid embolic systems
• Neutral Sentiment: Ownership and structure details may limit immediate financial impact — media reports note Medtronic expects to retain majority voting control (reported at least ~80.1% of voting stock), suggesting the IPO could be more about strategic focus and value crystallization than a full divestiture. Medtronic Spin-Off MiniMed Files for IPO
• Neutral Sentiment: Analyst stances remain cautious: some firms (e.g., Robert W. Baird) are maintaining “hold” ratings, reflecting mixed near-term views even as the strategic move unfolds. Robert W. Baird Remains a Hold on Medtronic (MDT)
• Negative Sentiment: Price-target trim: Truist cut its MDT price target modestly (from $110 to $107) and kept a “hold” rating, a sign some analysts see limited near-term upside despite the strategic separation. This analyst action could cap momentum until clearer financials for MiniMed and separation mechanics are disclosed. Medtronic price target lowered to $107 from $110 at Truist

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their price objective on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Robert W. Baird set a $103.00 price target on shares of Medtronic in a research report on Tuesday. Truist Financial dropped their price target on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research note on Thursday. The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Finally, Daiwa Capital Markets lifted their target price on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $109.94.

Medtronic Trading Up 0.2%

Shares of NYSE:MDT opened at $98.63 on Friday. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $106.33. The company’s 50 day moving average is $97.38 and its two-hundred day moving average is $93.35. The company has a market cap of $126.45 billion, a PE ratio of 26.59, a P/E/G ratio of 2.59 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is currently 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).